

2017 Latin America Tumor Marker Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

https://marketpublishers.com/r/227F9E0FECDEN.html

Date: February 2017

Pages: 550

Price: US\$ 7,065.00 (Single User License)

ID: 227F9E0FECDEN

Abstracts

This new 7-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer



therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.



Technology Assessment

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies.

Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Abbott

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics/Theradiag

bioMerieux



Bio-Rad	
CellSearch	
Cepheid	
Correlogic Systems/Vermillion	
Decode Genetics	
Diadexus	
DiaSorin	
Eiken Chemical	
Elitech Group	
Enterix/Clinical Genomics	
Enzo Biochem	
Epigenomics	
Exact Sciences	
Fujirebio	
Guided Therapeutics	
Hologic/Gen-Probe	
Kreatech/Leica	
Kyowa Medex	
Mackay Life Sciences	
Myriad Genetics	



OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher/Affymetrix
Tosoh
Veridex
Wako Pure Chemicals



Wallac/PE

Zilla/Alere

Contains 550 pages and 42 tables



Contents

I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. BREAST CANCER
 - 2. LUNG CANCER
 - 3. COLON AND RECTUM CANCER
 - 4. PROSTATE CANCER



- 5. STOMACH CANCER
- 6. LEUKEMIA
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SKIN CANCER
- 10. UTERINE CANCER
- 11. OVARIAN CANCER
- 12. BLADDER CANCER
- B. Major Current and Emerging Cancer Diagnostic Tests
 - 1. INTRODUCTION
 - 2. TUMOR MARKER CLASSIFICATION
 - 3. ACTH
 - 4. ALPHA-FETOPROTEIN (AFP)
 - 5. BETA-2 MICROGLOBULIN
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. CALCITONIN
 - 10. CARCINOEMBRIONIC ANTIGEN (CEA)
 - 11. ESTROGEN AND PROGESTERONE RECEPTORS
 - 12. FERRITIN
 - 13. GASTRIN
 - 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
 - 15. INSULIN
 - 16. NSE
 - 17. OCCULT BLOOD
 - 18. PAP SMEAR/HPV
 - 19. PROSTATIC ACID PHOSPHATASE (PAP)
 - 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
 - 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
 - 22. T AND B LYMPHOCYTES
 - 23. TDT
 - 24. THYROGLOBULIN
 - 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
 - 26. BIOCHEMICAL TUMOR MARKERS
 - 27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2



BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. POLYPEPTIDE GROWTH FACTORS
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha-Interferon

Gamma-Interferon Interleukin-1 (IL-1)

B Cell Growth Factors

Macrophage Activating Factor

B Cell Growth Factor (BCGF)

32. IMMUNOHISTOCHEMICAL STAINS



33. EMERGING TUMOR MARKERS

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2



Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opioid Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL



Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. MONOCLONAL AND POLYCLONAL ANTIBODIES
 - 2. IMMUNOASSAYS
 - 3. MOLECULAR DIAGNOSTICS
 - 4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. ARTIFICIAL INTELLIGENCE
 - 6. FLOW CYTOMETRY
 - 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
 - 8. BIOSENSORS
 - 9. COMPETING/COMPLEMENTING TECHNOLOGIES
- E. Personal Testing

VIII. COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES

Argentina



Brazil

Chile

Colombia

Mexico

Peru

Venezuela

IX. COMPETITIVE PROFILES

Abbott

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics



OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Thermo

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS



List Of Tables

LIST OF TABLES

Argentina Cancer Diagnostic Volume Forecasts by Test

Argentina Cancer Diagnostics Sales Forecasts by Test

Brazil Cancer Diagnostic Volume Forecasts by Test

Brazil Cancer Diagnostics Sales Forecasts by Test

Chile Cancer Diagnostic Volume Forecasts by Test

Chile Cancer Diagnostics Sales Forecasts by Test

Colombia Cancer Diagnostic Volume Forecasts by Test

Colombia Cancer Diagnostics Sales Forecasts by Test

Mexico Cancer Diagnostic Volume Forecasts by Test

Mexico Cancer Diagnostics Sales Forecasts by Test

Peru Cancer Diagnostic Volume Forecasts by Test

Peru Cancer Diagnostics Sales Forecasts by Test

Venezuela Cancer Diagnostic Volume Forecasts by Test

Venezuela Cancer Diagnostics Sales Forecasts by Test Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis



Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis



I would like to order

Product name: 2017 Latin America Tumor Marker Diagnostics Market: Sales Forecasts and Strategies,

Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

Product link: https://marketpublishers.com/r/227F9E0FECDEN.html

Price: US\$ 7,065.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/227F9E0FECDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



